Relying on Renagel
In the second of a two-part series focused on Genzyme's European operations, In Vivo Europe Rx looks at how Genzyme is addressing the challenges facing Renagel's uptake in Europe-cost-conscious reimbursement authorities, cheaper competitors and conservative physicians-in order to secure its most important mid-term growth source.
You may also be interested in...
Actelion didn't exactly hit the jackpot when OGS signed the Swiss company up to market its embattled Zavesca in Europe. But the move will cost Actelion little, and highlights that company's emerging status as a product-focused and independent biotech company, and a valuable marketing partner for niche drugs.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.
COVID-19 has triggered a dramatic shift toward virtual consultations and telemedicine, encouraged by more relaxed regulations and payer support.